Mamia Zodelava

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

Antonio Palumbo, Roman Hájek, Michel Delforge et al. · New England Journal of Medicine · 2012 · 739 citations · Full text

Medicine, Hematology, Pharmacotherapy +16

Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status

Jörge E. Cortes, Hagop M. Kantarjian, James M. Foran et al. · Journal of Clinical Oncology · 2013 · 361 citations · Full text

Medicine, Hematology, Oncology +15

AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study.

Jörge E. Cortes, James M. Foran, Darejan Ghirdaladze et al. · Blood · 2009 · 66 citations

Medicine, Medicinal Chemistry, Oncology +11

Pharmacokinetic and Safety of CT-P10, a Biosimilar Candidate to the Rituximab Reference Product, in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma (AFL)

Bertrand Coiffier, Juan‐Manuel Sancho, Wojciech Jurczak et al. · Blood · 2016 · 13 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +9

Phase 1 AML Study of AC220, a Potent and Selective Second Generation FLT3 Receptor Tyrosine Kinase Inhibitor

Jörge E. Cortes, Darejan Ghirdaladze, James M. Foran et al. · Blood · 2008 · 12 citations

Medicine, Oncology, Pharmacology +11